April 24, 2024
Entera (ENTX) & Protara (TARA), Bones and Bladders
Coverage Universe
Bones and Bladders In our initial note on Entera Bio (Nasdaq: ENTX), we turned their pipeline chart upside down by focusing on their earliest stage program, an oral dual-acting GLP-1/Glucagon […]
April 3, 2024
A Little of Everything, Pain (XENE), Obesity (VERU), Radiopharmaceuticals (CLRB), and a High-Stakes Data Readout
Coverage Universe
Structure Matters Investors ignore structure at their peril. In previous notes, we have highlighted how finance structures limited the impact of positive news for companies who entered into tranched financings, […]
March 14, 2024
NKTR, Obesity, and OPTN (OptiNose): A Binary Bet Worth Taking?
Coverage Universe
In a September 2023 note, we highlighted Nektar Therapeutics (Nasdaq: NKTR) as an interesting negative EV name investors should have on their radars. Although the stock has appreciated nicely since […]
February 28, 2024
Rybelsus Redux: Entera Bio (Nasdaq: ENTX) & Oral GLP-1s for Obesity
Uncategorized
Over our last few notes, we have thrown around some micro/small cap names that could benefit from the ongoing investor infatuation around development-stage obesity assets. So, in keeping with that […]
February 11, 2024
A Quick Pre-Super Bowl Update On A Few Names In Our Universe
Uncategorized
Long-tenured Xenon Pharmaceutical (Nasdaq: XENE) shareholders may have had a blast of nostalgia when the company’s CEO discussed plans to revisit their sodium channel, Nav1.7 program for pain, at their […]
January 28, 2024
Adage and Perceptive’s Curious GLP-1 Bet
Coverage Universe
What we are about to present is a trade idea. It landed on our radar after we saw this company pivot to focus on one of the biggest medical trends […]
January 15, 2024
Cellectar (CLRB) Delivers at JPM and a New(ish) Name
Uncategorized
Last Monday, Cellectar Biosciences (Nasdaq: CLRB) reported topline data from their pivotal study with their radiopharmaceutical CLR 131 in the rare cancer indication, Waldenstrom’s macroglobulinemia (WM). The data were expected […]
January 1, 2024
Names We’re Watching in 2024
Coverage Universe
Xenon Pharmaceuticals (Nasdaq: XENE) Xenon always issues a press release heading into the JP Morgan conference outlining their plans for the year, so investors should get clarity on their depression/mood […]
December 17, 2023
TARA: A New Name We’re Watching
Uncategorized
A respected biotech executive, and active investor, we know well, recently suggested we look at Protara Therapeutics (Nasdaq: TARA). Our interest was quickly piqued when we saw a ~$30mm valuation, […]
December 3, 2023
Follow-Up Note on Xenon & Fennec a Commercial Name to Watch
Coverage Universe
Xenon Cashed Up For Depression, Epilepsy, and Maybe More Last month we published a note highlighting Xenon Pharmaceuticals (Nasdaq: XENE) and two impending Phase 2 data readouts that should be […]